LabConnect Expands
LabConnect LLC, a global provider of central laboratory and support services for biopharmaceutical, medical device, and contract research organization, has completed phase one of a 11,000 square foot facility expansion in Johnson City, Tennessee, USA.
LabConnect LLC (Seattle, Washington, USA), a global provider of central laboratory and support services for biopharmaceutical, medical device, and contract research organization, has completed phase one of a 11,000 square foot facility expansion in Johnson City, Tennessee, USA. The new space will significantly increase the capacity for peripheral blood mononuclear cell (PBMC) processing and allow LabConnect to better serve its clients.
Following the completion of phase one of its expansion LabConnect will proceed with stages two and three, which include the addition of more offices and project management space, and building out the PBMC laboratory capabilities.
“We have grown every year since our founding in 2002, and we are committed to maintaining our facilities with cuttingâedge technology,” said Eric Hayashi, president and CEO of LabConnect. “It is an exciting time to be building our business, constantly improving sample testing services to meet clients’ needs, and helping to save lives while supporting clinical trials.”
The expansion is scheduled to be complete in September 2018. For more information, please visit www.labconnectllc.com
Using GC-MS to Investigate the Aroma Composition of Cheese
October 10th 2024Researchers from the Department of Bioscience and Technology for Food, Agriculture and Environment at the University of Teramo (Italy) used gas chromatography-mass spectrometry (GC-MS) investigated the contribution of Kluyveromyces marxianus to the gross composition and aroma profile of cow cheeses.
